• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

    2/14/23 3:01:05 PM ET
    $PHAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAS alert in real time by email
    SC 13G/A 1 rocksprings-phas123122a3.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*



    PhaseBio Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value, $0.001 per share

    (Title of Class of Securities)

     

    717224109

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     


     

    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Master Fund LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    PN

     

     
     

     

    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    PhaseBio Pharmaceuticals, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    1 Great Valley Parkway, Suite 30

    Malvern, PA 19355

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”); and

    iii. Rock Springs Capital Master Fund LP (“Master Fund”).

    This Statement relates to Shares (as defined herein) held directly by the Master Fund, which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

    Rock Springs Capital Master Fund LP

    c/o Walkers Corporate Limited

    Cayman Corporate Centre

    27 Hospital Road

    George Town, Grand Cayman, KY1-9008, Cayman Islands

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

    Rock Springs Capital Master Fund LP - Cayman Islands

     (d) Title of Class of Securities

    Common Stock, par value, $0.001 per share (the “Shares”)

     (e) CUSIP No.:

    717224109

     
     

     

    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 717224109
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of the date of this filing, each of RSC and RSCM may be deemed to be the beneficial owners of 0 Shares, which amount includes 0 Shares directly beneficially owned by the Master Fund, and 0 Shares directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 49,858,116, the amount of Shares outstanding as reported in the Issuer’s Form 10-Q filed on August 12, 2022.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 0%

    Rock Springs Capital LLC: 0%

    Rock Springs Capital Master Fund LP: 0%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date herof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

     

     
     
    CUSIP No.  717224109
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 14, 2023

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

     

     

     

     

     

    Get the next $PHAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAS

    DatePrice TargetRatingAnalyst
    9/28/2022$15.00 → $1.00Buy → Hold
    Stifel
    10/13/2021$15.00Buy
    Stifel
    More analyst ratings

    $PHAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

      Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers

      10/24/22 8:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

      PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities. "The second quarter of 2022 marked a period of continued progress for PhaseBio," said Jonathan Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. "Following a successful meeting with the U.S. Food and Drug Administration (FDA) during our pre-biologics license application (pre-BLA) meeting earlier this year and as previously disclosed, we have been focused on clinical developmen

      8/12/22 8:30:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

      Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if approved Presented positive results from Phase 2b trial for bentracimab at ACC.22 Completed the Process Performance Qualification (PPQ) campaign demonstrating commercial scale manufacturing ability for bentracimab PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financia

      5/16/22 6:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Leadership Updates

    Live Leadership Updates

    See more
    • PhaseBio Names Jonathan Birchall as Chief Commercial Officer

      PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer. "Jonathan brings to PhaseBio deep commercial expertise in the critical-care setting, which he gained through his leadership of the thrombolytics franchise at Genentech," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "With his background and track record of success, Jonathan has the experience necessary to lead our commercial organization and joins us at a pivotal time in PhaseBio's evolution as we begin prepar

      11/18/21 4:01:00 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Appoints William D. Humphries to Board of Directors

      PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Justin Klein, M.D., J.D., is stepping down from his role as director, effective immediately. "Bill's deep commercial expertise gained through his leadership roles at numerous specialty pharmaceutical companies will be an invaluable addition to our already robust board of directors," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "Bill joins us at an exciting and pivotal time in PhaseBio's growth, as

      9/15/21 8:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    SEC Filings

    See more
    • PhaseBio Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)

      11/29/23 4:55:08 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by PhaseBio Pharmaceuticals Inc.

      NT 10-Q - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)

      11/15/23 4:17:16 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

      8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)

      10/3/23 7:17:19 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PHAS
    Financials

    Live finance-specific insights

    See more
    • PhaseBio Pharmaceuticals downgraded by Stifel with a new price target

      Stifel downgraded PhaseBio Pharmaceuticals from Buy to Hold and set a new price target of $1.00 from $15.00 previously

      9/28/22 12:51:14 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on PhaseBio Pharmaceuticals with a new price target

      Stifel resumed coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00

      10/13/21 7:53:54 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on PhaseBio Pharmaceuticals with a new price target

      Needham reiterated coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $16.00 previously

      6/17/21 11:20:30 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

      PhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness to accept a BLA with data from 25-30 uncontrolled bleeding patients, in addition to surgical patients enrolled to date, to potentially support a label that includes both surgical and uncontrolled bleeding indications To date, PhaseBio has enrolled 35 uncontrolled bleeding patients and has completed enrolling surgical patients in the Phase 3 REVERSE-IT trial Conference call and webcast today at 8:30 a.m. ET PhaseBio Pharmaceuticals, Inc. (NASD

      5/16/22 6:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding

      Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients Bentracimab appeared well tolerated with no drug-related serious adverse events Results presented today in Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions and accepted for publication in NEJM Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group Investor webcast scheduled for today at 12:30 p.m. ET PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHA

      11/15/21 11:31:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting

      Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association's Scientific Sessions 2021 Guest speakers include Deepak L. Bhatt, M.D., MPH; Charles Pollack, M.D.; and Philippe Gabriel Steg, M.D. Video webcast to be held on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host an investor call on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) to discuss the results

      11/10/21 8:01:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)

      2/14/23 4:45:46 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)

      2/14/23 3:01:05 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)

      2/14/23 2:26:56 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Van Den Broek Richard

      4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)

      5/19/23 4:18:54 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Thorp Clay

      4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)

      5/19/23 4:18:34 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Humphries William D.

      4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)

      5/19/23 4:18:07 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care